BioVie Inc.

BIVI

$2.28

+5.56%

2026-08-31 16:00:01 EDT+$0.12

Healthcare

Biotechnology

NASDAQ

Active Trading

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United ...

Price Action of BIVI

$2.28

+5.56%+$0.12

High—

Low—

52W High-39.8%

Rel. vol—

Interval

Range4.6h

Volume—SMA5SMA10

—

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company headquartered in Carson City, Nevada, founded in 2013 and formerly known as NanoAntibiotics, Inc. The company focuses on developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and long COVID, as well as ...BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company headquartered in Carson City, Nevada, founded in 2013 and formerly known as NanoAntibiotics, Inc. The company focuses on developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and long COVID, as well as advanced liver disease. Key product candidates include BIV201, which has completed Phase IIa clinical trials for ascites due to chronic liver cirrhosis, and NE3107, which is in Phase III trials for mild-to-moderate Alzheimer's disease and Phase I trials for Parkinson's disease. Additionally, NE3107 is being investigated preclinically for multiple myeloma and prostate cancer. BioVie is led by CEO Cuong Viet Do, who also serves as President, and the company has a small team of 13 full-time employees. Financially, BioVie is a pre-revenue company with no gross profit, yet it maintains a strong balance sheet with a current ratio of 3.594 and no significant debt (debt-to-equity ratio of 0.027). The company went public in September 2020 and trades on the NASDAQ Capital Market. BioVie is committed to 'unlocking the science of longevity' and aims to empower patients by providing hope and control over their health. The company faces challenges typical of clinical-stage biotech, including negative profitability (net income per share of -$2.64) and high operating expenses, but its cash position and ongoing clinical trials position it for potential future growth in the neurodegenerative and liver disease markets.ExpandCollapse

Founded

2013

Employees

CEO

Cuong Viet Do

Full Name

BioVie Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-126.02%

Market Cap

$0.02B

Current Ratio

3.59

WACC

4.52%

ROIC

-212.12%

Contact Information

https://bioviepharma.com

775 888 3162

680 West Nye Lane, Carson City, NV 89703

Key Metrics of BIVI

Snapshot

Latest / TTM · 6 periods

Market Cap

$17.20M

ROCE

-216.7%

EV / EBITDA

-0.30x

-216.7% YoY

FCF Yield

-124.3%

+135215.2% YoY

Cash Conversion Cycle

-7582.4d

Current Ratio

3.59

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of BIVI

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.63x

n/a

Debt / Equity

0.03

n/a

Current Ratio

3.59

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of BIVI

Upcoming

Sep 30, 2026In 26 days
Q1 FY2027 · Estimated results
Est. EPS $0.00 · Revenue $0.00
Jun 30, 2027
FY2027 · Estimated annual results
Est. EPS $-0.63 · Revenue $367.51M · 1 analysts
Jun 30, 2028
FY2028 · Estimated annual results
Est. EPS $-0.57 · Revenue $0.00 · 1 analysts
Jun 30, 2029
FY2029 · Estimated annual results
Est. EPS $-0.55 · Revenue $0.00 · 1 analysts

Recent history

Aug 13, 2026
FY2026 · Annual results
EPS $-3.05 · Revenue $0.00
View filing
May 11, 2026
Q3 FY2026 · Results reported
EPS $-0.70 · Revenue $0.00
View filing
Feb 6, 2026
Q2 FY2026 · Results reported
EPS $-0.77 · Revenue $0.00
View filing
Nov 10, 2025
Q1 FY2026 · Results reported
EPS $-0.98 · Revenue $0.00
View filing
Aug 15, 2025
FY2025 · Annual results
EPS $-12.12 · Revenue $0.00
View filing
May 12, 2025
Q3 FY2025 · Results reported
EPS $-1.50 · Revenue $0.00
View filing

Financial Statements of BIVI

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-22.1M	-25.8%	-7.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-19.0B	-99897.9%	+44.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	2.7%	+45.7%	+41.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.59x	-60.5%	-63.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$14250.5B	+66089921.7%	-18.6%

Actual vs Estimate

A Jun 30Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-3.05 vs -1.19	-156.3%	-0.75 vs -0.52	-44.2%
Revenue Surprise	$0 vs $2.1M	-100.0%	—	—

Insider Transactions of BIVI

Acquisitions (A)

Since Jan 5, 2026

Disposals (D)

Since Jan 5, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 28, 2026	Palumbo Joseph M	officer: Chief Medical Officer	Common Stock	A	4,843	$2.16
Aug 28, 2026	Chappell Amy Suzon	director	Common Stock	A	727	$2.16
Aug 28, 2026	KIM JOANNE WENDY	officer: Chief Financial Officer	Common Stock	A	2,500	$2.18
Aug 27, 2026	DO CUONG V	director, officer: President & CEO	Common Stock	A	15,210	$2.08
Jan 5, 2026	Palumbo Joseph M	officer: Chief Medical Officer	Stock Option (right to buy)	A	132,000	$1.31

Leadership Team of BIVI

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Cuong Viet Do	President, Chief Executive Officer & Director	USD 736,000	Male	1966	Active
Joseph Palumbo	Executive Vice President of R&D and Chief Medical Officer	USD 645,250	—	1961	Active
Joanne Wendy Kim	Chief Financial Officer, Treasurer & Corporate Secretary	USD 389,375	Female	1956	Active
Penelope Markham	Senior Vice President of Liver Disease & Long COVID Programs	—	—	1966	Active
Denise Smith	Senior Vice President of Manufacturing & Development	—	Female	—	Active
Clarence N. Ahlem	Senior Vice President of Operations	—	Male	1956	Active
David Morse	Senior Vice President & Chief Regulatory Officer	—	Male	—	Active
Christopher L. Reading	Senior Vice President of Alzheimer's Disease Program	—	—	1948	Active

Recent News of BIVI

Seeking Alpha8/12/2026Neutral

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

Proactive Investors8/7/2026Neutral

Parkinson's drug developers are betting big on inflammation

For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease.

Proactive Investors - Finance8/7/2026Neutral

Vaalco Energy quarter sales jump, ups guidance

Vaalco Energy Inc (LSE:EGY) told investors that second-quarter sales jumped 47% from the previous three months as higher Gabon liftings and Egyptian volumes...

Proactive Investors - Finance8/6/2026Neutral

Apple App Store revenue ticks up despite falling downloads

Apple Inc (NASDAQ:AAPL, XETRA:APC) App Store revenue rose 0.6% year-over-year in the first 35 days of its fiscal fourth quarter to $3.4 billion, up from...

Proactive Investors - Finance8/6/2026Neutral

Uber price target lowered by Bank of America despite higher earnings outlook

Uber Technologies Inc (NYSE:UBER, XETRA:UT8) saw its price target lowered to $101 from $103 by Bank of America, which maintained a ‘Buy’ rating following...

Historical Employee Count of BIVI

Current

Change

+0.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Jun 30, 2026	13	10-K	Aug 13, 2026	View
Jun 30, 2025	13	10-K	Aug 15, 2025	View
Jun 30, 2024	14	10-K	Sep 30, 2024	View
Jun 30, 2023	18	10-K	Aug 16, 2023	View
Jun 30, 2022	13	10-K	Sep 27, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

BioVie Inc.